Yelena Y. Janjigian, MD, FASCO, on CLARITY-Gastric 01: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer
ESMO Congress 2026
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy after at least one prior therapy for gastroesophageal cancer expressing CLDN18.2 in ≥ 25% tumor cells with membranous staining at any intensity (Abstract LBA7).
Sanjiv S. Gangaram-Panday, PhD, of Erasmus University, presents 5-year outcomes from the Surgery As Needed for Oesophageal Cancer (SANO) trial. The study previously demonstrated that active surveillance is noninferior to standard surgery in terms of 2-year overall survival in patients with a complete clinical response after neoadjuvant chemoradiotherapy; active surveillance also resulted in improved quality of life (Abstract LBA78).
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, reviews interim overall survival and safety results from a randomized phase III study evaluating durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with advanced/recurrent endometrial cancer (Abstract LBA37).
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial carcinoma (Abstract LBA12).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate arcotatug tavatecan in previously treated patients with gastric or gastroesophageal junction (GEJ) cancer. Dr. Smyth was a co-chair of the proffered paper session that featured the abstract (Abstract LBA77).
The phase III HARMONi-GI1 trial is evaluating the efficacy and safety of ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy vs durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer. At the ESMO Congress 2026, invited discussant James J. Harding, MD, reviewed the results from the preplanned interim analysis (Abstract LBA8).
